Actonel (Risedronate) — Competitive Intelligence Brief

Actonel (Risedronate) (Actonel (Risedronate)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Bone metabolism / Rheumatology.

phase 3 Bisphosphonate Hydroxyapatite (bone mineral); osteoclast function inhibition Bone metabolism / Rheumatology Small molecule

Target snapshot

Actonel (Risedronate) (Actonel (Risedronate)) — M.D. Anderson Cancer Center. Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Actonel (Risedronate) TARGET	Actonel (Risedronate)	M.D. Anderson Cancer Center	phase 3	Bisphosphonate	Hydroxyapatite (bone mineral); osteoclast function inhibition
Boniva	IBANDRONIC ACID	Hoffmann La Roche	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	2003-01-01
Skelid	TILUDRONIC ACID		marketed	Bisphosphonate	72 kDa type IV collagenase	1997-01-01
Aredia	PAMIDRONIC ACID		marketed	Bisphosphonate	Farnesyl pyrophosphate synthase	1991-01-01
Didronel	ETIDRONIC ACID	Procter And Gamble	marketed	Bisphosphonate		1977-01-01
Hormone Replacement Therapy and Etidronate	Hormone Replacement Therapy and Etidronate	British Thoracic Society	marketed	Hormone replacement therapy combined with bisphosphonate	Estrogen receptor (HRT component); bone hydroxyapatite and osteoclast function (etidronate component)
Risedronate/Cholecalciferol combination	Risedronate/Cholecalciferol combination	Hanlim Pharm. Co., Ltd.	marketed	Bisphosphonate + vitamin D3 combination	Osteoclast farnesyl pyrophosphate synthase (risedronate); vitamin D receptor (cholecalciferol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

1. · 2 drugs in this class
2. Amgen · 2 drugs in this class
3. National Taiwan University Hospital · 2 drugs in this class
4. Sanofi · 2 drugs in this class
5. Ludwig-Maximilians - University of Munich · 2 drugs in this class
6. Chinese University of Hong Kong · 1 drug in this class
7. Chinese Society of Lung Cancer · 1 drug in this class
8. Aarhus University Hospital · 1 drug in this class
9. Eisai Inc. · 1 drug in this class
10. Daiichi Sankyo Co., Ltd. · 1 drug in this class